Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Active not recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Sarcoma 1

Conditions

Small Cell Lung Carcinoma 9Burkitt Lymphoma 7Lung Neoplasms 6Lymphoma, Non-Hodgkin 5Leukemia, Myeloid, Acute 5Carcinoma, Non-Small-Cell Lung 5Precursor Cell Lymphoblastic Leukemia-Lymphoma 4Lymphoma, Large B-Cell, Diffuse 4Sarcoma, Ewing 3Recurrence 3Precursor T-Cell Lymphoblastic Leukemia-Lymphoma 3Plasmablastic Lymphoma 3Multiple Myeloma 3Lymphoma 3Leukemia 3Hodgkin Disease 3Parkinson Disease 4, Autosomal Dominant Lewy Body 2Myelodysplastic Syndromes 2Lymphoproliferative Disorders 2Lymphoma, T-Cell 2Lymphoma, Mantle-Cell 2Lymphoma, Follicular 2Lymphoma, B-Cell 2Immunoblastic Lymphadenopathy 2HIV Infections 2Ganglioneuroblastoma 2Congenital Abnormalities 2Blast Crisis 2Anemia, Refractory, with Excess of Blasts 2Wilms Tumor 1

Interventions

Specimen Handling 6Magnetic Resonance Spectroscopy 6Biopsy 6Doxorubicin 5pembrolizumab 4X-Rays 4Phantoms, Imaging 4Nuclear Medicine Department, Hospital 4Cyclophosphamide 4liposomal doxorubicin 3fludarabine 3ulixertinib 2tipifarnib 2tazemetostat 2selpercatinib 2palbociclib 2larotrectinib 2ivosidenib 2fludarabine phosphate 2ensartinib 2atezolizumab 2anlotinib 2Temozolomide 2Radiation 2Irinotecan 2Ifosfamide 2Carboplatin 2Bevacizumab 2trifluridine tipiracil drug combination 1trastuzumab deruxtecan 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Sarcoma × Etoposide × 30 days × Clear all
NCT00077285 2026-05-22

Irinotecan and Carboplatin as Upfront Window Therapy in Treating Patients With Newly Diagnosed Intermediate-Risk or High-Risk Rhabdomyosarcoma

Memorial Sloan Kettering Cancer Center

Phase 2 Active not recruiting
65 enrolled
Sarcoma

Malignant mesenchymal tumor, Rhabdomyosarcoma, Sarcoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡